Christopher Chapron

Christopher Chapron started their work experience in 2000 as an Associate Scientist at Cytyc Corporation. Christopher then moved on to Idenix Pharmaceuticals, where they held various roles such as Research Associate I, Research Associate II, Senior Research Associate, and Research Scientist I. During their time at Idenix Pharmaceuticals, they developed replicons to evaluate lead compound activity, performed resistance selection experiments, and evaluated and characterized lead compounds for activity against human cellular DNA and RNA polymerases. In 2015, they joined Scholar Rock as a Principal Research Associate and later became a Senior Scientist. Christopher'srole at Scholar Rock involves discovering and developing new medicines for various serious diseases by targeting growth factors.

Christopher Chapron holds a Masters of Science degree in Microbiology from the University of New Hampshire. The exact duration of their studies at this institution is unknown.